Drug Profile
Research programme: nucleoside reverse transcriptase inhibitors - Presidio Pharmaceuticals
Alternative Names: MIV 410; PPI 810; PPI-801; PPI-802Latest Information Update: 27 Nov 2012
Price :
$50
*
At a glance
- Originator Medivir AB
- Developer Presidio Pharmaceuticals
- Class
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cytomegalovirus infections; HIV infections
Most Recent Events
- 30 Sep 2012 Discontinued - Preclinical for Cytomegalovirus infections in USA (PO)
- 30 Sep 2012 Discontinued - Preclinical for HIV infections in USA (PO)
- 30 Aug 2007 Preclinical development is ongoing